Abstract
Human pluripotent stem cells (hPSCs) are a powerful platform for disease modeling and drug discovery. However, the introduction of known pathogenic mutations into hPSCs is a time-consuming and labor-intensive process. Base editing is a newly developed technology that enables facile introduction of point mutations into specific loci within the genome of living cells. Here, we design an all-in-one episomal vector that expresses a single guide RNA (sgRNA) with an adenine base editor (ABE) or a cytosine base editor (CBE). Both ABE and CBE can efficiently introduce mutations into cells, A-to-G and C-to-T, respectively. We introduce disease-specific mutations of long QT syndrome into hPSCs to model LQT1, LQT2, and LQT3. Electrophysiological analysis of hPSC-derived cardiomyocytes (hPSC-CMs) using multi-electrode arrays (MEAs) reveals that edited hPSC-CMs display significant increases in duration of the action potential. Finally, we introduce the novel Brugada syndrome-associated mutation into hPSCs, demonstrating that this mutation can cause abnormal electrophysiology. Our study demonstrates that episomal encoded base editors (epi-BEs) can efficiently generate mutation-specific disease hPSC models.
Introduction
Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) () and the closely related human induced pluripotent stem cells (iPSCs) (), can self-renew and differentiate into various cell types. Due to these properties, these stem cells hold great promise for modeling mammalian organ development, studying disease mechanisms and pathways, and developing future therapies (Wang et al., 2012, ; ; ). However, to realize these potential applications, genes of interest often need to be engineered in the cell. For example, iPSCs derived from patients often contain genetic mutations that need to be corrected prior to conducting specific therapies (). For disease modeling with normal hPSCs, pathogenic mutations need to be introduced into cells to generate disease models (; Xie et al., 2019). Therefore, it is crucial to develop methods and technologies for efficient genetic manipulation of stem cells.
The RNA-guided CRISPR–Cas9 system is a powerful tool for genome editing in hPSCs (; Xie et al., 2017). In this system, a Cas9 nuclease and a single guide RNA (sgRNA) form a Cas9–sgRNA complex, which recognizes a specific DNA sequence that is complementary to the sgRNA, and subsequently generate a site-specific double-strand break (DSB) (; ; ). The DSBs are typically repaired by the cell’s endogenous DNA repair machinery through non-homologous end-joining (NHEJ) or microhomology mediated end-joining (MMEJ), resulting in non-specific small insertions and deletions (indels) around the cut site, which can be useful for generating loss-of-function mutations (). These DSBs can also be repaired by homology-directed repair (HDR) using an introduced DNA repair template, such as a double-stranded DNA donor plasmid or single-stranded donor DNA oligonucleotides (ssODN), resulting in the introduction of precise modifications (Wang et al., 2012; ). However, the HDR pathway is strongly disfavored in most cell types and requires special cellular machinery that is only present during cellular replication (Wang et al., 2012, ). Furthermore, the use of nuclease Cas9 to mediate DSBs results in potential undesired translocations or DNA rearrangements.
Base editing is a new genome-editing technology that directly generates precise point mutations without generating DSBs (; ). Base editors comprise fusions between a catalytically impaired Cas9 nuclease and a single-stranded DNA (ssDNA) specific deaminase enzyme. Upon binding to its target DNA, base pairing between the sgRNA and the target DNA strand results in the displacement of a small segment of single-strand DNA as an “R-loop” (; ). DNA bases within this ssDNA are therefore substrates for deamination and are subsequently modified by the deaminase enzyme. Two classes of DNA base editor have so far been developed—cytosine base editors (CBEs) convert a C⋅G base pair into a T⋅A base pair (), and adenine base editors (ABEs) convert an A⋅T base pair into a G⋅C base pair (). Base editors hold great promise for the genetic modification of hPSCs ().
The long QT syndrome (LQTS) is a heart disorder that is characterized by the prolongation of the QT interval of surface electrocardiograms and is associated with malignant arrhythmias, syncopal episodes, torsade de pointes form ventricular tachycardias, and an increased risk of sudden cardiac death (). Mutations in the KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A genes (LQT3) account for the three most common pathogenic variants that are clinically annotated for LQTS (). In addition to LQTS, mutations in SCN5A have been shown to induce Brugada syndrome (BrS) (Wilde and Amin, 2018). We and others have demonstrated that hPSCs can be used for modeling LQTS (; ).
We previously used an episomal vector to express Cas9 and sgRNAs (epiCRISPR), and achieved high efficiency of genome editing through the NHEJ/MMEJ pathway (Xie et al., 2017; ). This episomal vector can replicate during cellular division in eukaryotes (), permitting the continuous expression of Cas9 and sgRNAs in cells. The vector also contains a drug resistance gene, allowing for the enrichment of transfected cells by drug selection. In this study, we generate episomal vectors that express base editors (epi-BEs) and achieve high efficiency of precise genome editing in hPSCs. As a proof of concept, we first demonstrate that these epi-BEs can efficiently introduce mutations into hPSCs to generate LQTS models. We then evaluate a novel mutation on SCN5A for developing BrS. Our study demonstrates that these epi-BEs are a simple and efficient platform to generate human disease models in stem cells.
Materials and Methods
Cell Culture
Human ESCs (H9, WA09, Wicell, Madison, WI, United States) and iPSCs were cultured on Matrigel-coated plates (ESC qualified, BD Biosciences, San Diego, CA, United States) using hESC mTeSR-1 cell culture medium (StemCell Technologies, Vancouver, Canada), whereas HEK293T and HeLa cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Gibco). All media contained 100 U/ml of penicillin and 100 mg/ml of streptomycin. Cells were cultured at 37°C with 5% CO2 in a humidified and mycoplasma negative incubator.
Plasmid Construction
Epi-ABEmax/epi-AncBE4max: KO plasmid (Addgene #135970) was PCR-amplified using primers EBV-F/EBV-R to generate Fragment 1, which contained oriP/EBNA1, gRNA expression cassette (hU6 promoter and gRNA scaffold) and EF1A core promoter. Fragment 2 was synthesized by GENEWIZ (Suzhou, China) and was used to express blasticidin S deaminase (BSD), and then Fragment 2 was PCR-amplified using primers BSD-F/BSD-R. Fragment 3 contained full ABE or CBE and was obtained from pCMV_ABEmax (Addgene #112095) or pCMV_AncBE4max (Addgene #112094); this was amplified by PCR using primers ABEmax-F/ABEmax-R or AncBE4-F/AncBE4-R. All three fragments were cloned together by NEBuilder Assembly Tool (NEB) following the manufacturer’s protocol, resulting in epi-ABEmax-hU6 or epiAncBE4-hU6. Furthermore, hU6 was replaced by mU6 to eventually result in epi-ABEmax or epi-AncBE4max. mU6 was synthesized by GENEWIZ (Suzhou, China) and PCR-amplified using primers mU6-F/mU6-R, then cloned into the epi-ABEmax-hU6 or epi-AncBE4max-hU6 backbone, which was PCR-amplified using primers EBV-2-F/EBV-2-R. Sequences were verified by Sanger sequencing (GENEWIZ, Suzhou, China).
Epi-ABEmax-NG/epi-AncBE4max-NG: A portion of SpCas9-NG that contained the seven mutations (R1335V/L1111R/D1135V/G1218R/E1219F/A1322R/T1337R) was PCR-amplified from pX330-SpCas9-NG (Addgene #17919) using primers 1111-UP-F/1337-DOWN-R. This portion of SpCas9-NG was cloned into epi-ABEmax or epi-AncBE4max backbone, which was PCR-amplified using primers epi-backbone-F/epi-backbone-R, resulting in epi-ABEmax-NG or epi-AncBE4max-NG.
To express an sgRNA, the oligonucleotide duplexes were cloned into BspQI restriction sites of epi-ABEmax/epi-AncBE4 max/epi-ABEmax-NG/epi-AncBE4max-NG.
All primers are listed in Supplementary Table 1.
Base Editing and Blasticidin Selection
Cells were plated into 48-well plates and transfected the next day at approximately 70% confluency. Briefly, 500 ng of epi-ABEmax/epi-AncBE4max/epi-ABEmax-NG/epi-AncBE4 max-NG plasmid was transfected using Lipofectamine 3000 (Life Technologies) according to the manufacturer’s instructions at day 1. For H9 and iPSCs, cells were passaged on days 2, 6, and 11, respectively, and selected by blasticidin (Thermo Fisher Scientific) from day 2 to day 16. A 2.5 μg/ml of blasticidin was added into the growth media, except on days 2, 6, and 11, where 10, 5, and 0 μg/ml of blasticidin were used, respectively. For HeLa and HEK293T cells, 2.5 μg/ml of blasticidin was used from day 2 to day 16. Transfected cells were harvested for analysis on days 6, 11, and 16. The antibiotic screening time can be shortened when editing efficiency is enough, which has been discussed in detail in a recent work ().
The genomic DNA was isolated using QuickExtractTM DNA Extraction Solution (Lucigen) according to the manufacturer’s instructions. Targets of base editing were amplified by PCR using KOD DNA Polymerase (Toyobo). The PCR products were sequenced using Sanger sequencing, and the editing efficiency was analyzed by EditR ().
Off-Target Analysis
For each target site, five potential off-targets were selected based on Cas-Offinder1 () and PCR-amplified for Sanger sequencing.
Single Cell-Derived Clone Screen
The iPSCs were passaged with ethylenediaminetetraacetic acid (EDTA). Then, 1 × 105 cells were seeded on a Matrigel (Corning, United States) pre-coated 10 cm dish using E8 media (Cellapy, Beijing, China) with 2 μM of thiazovivin (TZV, Selleck, United States). Twenty-four hours later, the E8 media was replaced by new media without TZV. This media was changed every 2 days. Ten days after seeding, the single cell-derived clones were picked with a 1 ml sterile syringe and placed on a Matrigel pre-coated 24-well plate for cell expansion. Genomic DNA was extracted using the TIANamp Genomic DNA Kit (Tiangen Biotech, Beijing, China) for DNA sequencing.
Cardiomyocyte Differentiation
A chemically defined molecular-based method was applied for cardiomyocyte (CM) differentiation (). Briefly, cells (∼90% confluency) were seeded on a Matrigel pre-coated 6-well plate at a ratio of 1:6 in E8 media. The media was changed to CDM3 (consisted of RPMI 1640, 500 μg/ml of Oryza sativa-derived recombinant human albumin, and 213 μg/ml of L-ascorbic acid 2-phosphate) supplemented with 6 μM of CHIR99021 when the cells reached ∼75% confluency. After 48 h, the media was changed to CDM3 supplemented with 2 μM of Wnt-C59. After 2 days, the media was changed to CDM3 and refreshed every 2 days. After differentiation for 7–8 days, spontaneous contracting cells could be observed. On day 12, CMs were purified using a metabolic-selection method. Briefly, the medium consisted of RPMI 1640 without glucose, 213 μg/ml of L-ascorbic acid 2-phosphate, 500 μg/ml of Oryza sativa-derived recombinant human albumin, and 5 mM of sodium DL-lactate (Sigma, United States). After purification, CMs were cultured with RPMI 1640 and B27 (Life Technology, United States). For cellular maintenance, the medium was changed every 3 days.
Electrophysiological Test Using MEA
CMs were digested with Accutase (Thermo Fisher, United States). CytoView MEA24 plates (Axion Biosystems, Inc., Atlanta, United States) were pre-coated overnight by 0.5% Matrigel phosphate-buffered saline (PBS) solution. Then, 15,000 CMs were plated on each multi-electrode array (MEA) well with RPMI/B27 medium and cultured for 3 days. When the cellular electrophysiological activity became stable, the experimental data were recorded using Maestro EDGE (Axion Biosystems, Inc., Atlanta, United States) according to the MEA manual. The data were analyzed using the AxIS Navigator, Cardiac Analysis Tool, and IGOR software.
Clinical Data
The patient’s data were provided by Xin Hua Hospital Affiliated to Shanghai Jiao Tong University.
Quantification and Statistical Analysis
The editing efficiency was analyzed by EditR, which is an algorithm for predicting potential editing in a guide RNA region from a single Sanger sequencing run (). All data are shown as mean ± SD. Statistical analyses were conducted using Microsoft Excel. Two-tailed, unpaired Student’s t-tests were used to determine statistical significance when comparing two groups. A value of P < 0.05 was considered to be statistically significant (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ****P < 0.0001).
Results
Episomal Vector-Based Base Editors for Efficient Base Editing
We designed an all-in-one episomal vector-based system to express an sgRNA with an ABE (ABEmax, ), which we named epi-ABEmax, or a CBE (AncBE4max, ), which we named epi-AncBE4max. These vectors also express a BSD conferring resistance to blasticidin, which allows for enrichment of transfected cells through antibiotic selection (Figure 1A). First, we analyzed the capacity of the epi-ABEmax for base editing in two somatic cell lines (HEK293T and HeLa) and two hPSC lines (H9 and iPSCs). We selected two previously reported sgRNAs, targeting Site 1 and Site 2 (), to determine adenine base editing efficiency. The plasmid was delivered into cells using a lipid-based transfection, followed by blasticidin selection (Figure 1B). Editing efficiency was measured on days 6, 11, and 16. The maximum editing efficiencies were observed on days 6 and 11 for HEK293T and HeLa cells (Figures 1C,D). For H9 and iPSCs, the editing efficiency increased over time and seems to continue growing past day 16 (Figures 1E,F).
FIGURE 1
Next, we analyzed the capacity of the epi-AncBE4max for base editing in these four cell lines. We selected two gRNAs, targeting HEK3 (Site 3) () and FANCF (Site 4), to measure cytosine base editing efficiency. Similar to epi-ABEmax data, the maximum editing efficiencies were observed at days 6 and 11 for HEK293T and HeLa cells (Figures 1G,H). For H9 and iPSCs, the editing efficiency increased over time and seems to continue to increase past day 16 (Figures 1I,J). In summary, these epi-BEs enable efficient base editing in both somatic cells and hPSCs.
Base Editing of KCNQ1 for LQT1 Modeling
We next decided to show the utility of epi-BEs for modeling disease. For this, we introduced the pathogenic mutation L114P in KCNQ1, as annotated in previous literature (), into H9 cells. We designed a corresponding sgRNA (Figure 2A) that would install this mutation located at position 6 of the protospacer, counting the SpCas9 PAM as positions 21–23. Following a similar editing protocol as before, the editing efficiency reached up to 34% on day 16 (Supplementary Table 2 and Supplementary Figure 1A). We screened 52 single cell-derived clones, from which there were 26 heterozygous clones and 3 homozygous clones (Table 1). To test whether base editing influenced the pluripotency of H9 cells, immunofluorescence staining was performed for the pluripotency markers OCT-4 and SSEA-4. Besides, a higher standard, teratoma formation experiment was performed. We note that base editing did not influence marker expression, and that the cells can differentiate into three germ layer lineages after base editing (Supplementary Figure 2).
FIGURE 2
TABLE 1
| Gene | Mutation | Total number of clones | Heterozygous clones | Homozygous clones |
| KCNQ1 | L114P | 52 | 26 (50%) | 3 (5.8%) |
| KCNQ1 | R190Q | 77 | 22 (28.6%) | 6 (7.8%) |
| KCNH2 | Y616C | 4 | 4 (100%) | 0 (0) |
| KCNH2 | Y475C | 41 | 18 (40.9%) | 8 (19.5%) |
| SCN5A | E1784K | 107 | 32 (29.9%) | 5 (4.7%) |
| SCN5A | R1879W | 47 | 2 (4.3%) | 8 (17%) |
Summary of base editing efficiency.
Subsequently, heterozygous L114P-H9 cells were differentiated into CMs using a chemically defined, small molecule-based monolayer CM differentiation method (Figure 2B and Supplementary Figure 2) (). To test whether these CMs exhibited the LQT1 phenotype, electrophysiology was recorded using the local extracellular action potential (LEAP) assay, which is a high-throughput, non-invasive, label-free, and stable method to measure extracellular field potential (FP) from an intact CM syncytium (), which can be translated into an action potential (AP) (). Prolongation of the action potential duration (APD) and field potential duration (FPD) are the most important LQTS electrophysiological phenotypes at the cellular level (; ). APD at 50% (APD50) and 90% (APD90) in L114P-CMs were significantly longer than those in wild-type (WT)-CMs (Figures 2C–E). Corrected field potential duration (FPDc) in L114P-CMs was significantly longer than that in WT-CMs (Figures 2F,G). L114P-CMs also exhibited an abnormal AP profile, which resembles a closely coupled single triggered beat (Figure 2H).
To further test the capacity of these epi-BEs, we introduced another known pathogenic mutation (R190Q) () into KCNQ1 to model LQT1 (Supplementary Figures 3A,B). The editing efficiency reached 31% on day 16 (Supplementary Figure 1B and Supplementary Table 2). We screened 77 single cell-derived clones, of which there were 22 heterozygous clones and 6 homozygous clones (Table 1). We differentiated heterozygous R190Q-H9 cells into CMs and recorded electrophysiology by using the LEAP assay (Supplementary Figures 3C–G). Compared with WT-CMs, R190Q-CMs displayed significantly longer APD and FPDc. R190Q-CMs also exhibited an abnormal AP profile, resembling that of a closely coupled single triggered beat (Supplementary Figure 3H). Taken together, these data demonstrated that both L114P-CMs and R190Q-CMs recapitulated LQT1 phenotype.
Base Editing of KCNH2 for LQT2 Modeling
To model LQT2, we introduced a known pathogenic mutation Y616C () into the KCNH2 gene of H9 cells (Figure 3A). The editing efficiency reached 37% on day 16 (Supplementary Figure 1C and Supplementary Table 2). We screened four single cell-derived clones, all of which were heterozygous clones (Table 1). To test whether CMs exhibited the LQT2 phenotype, we differentiated the heterozygous Y616C-H9 cells into CMs, and electrophysiology was recorded by the LEAP assay (Figure 3B). APD50 and APD90 in Y616C-CMs were significantly longer than those in WT-CMs (Figures 3C–E). FPDc in Y616C-CMs was significantly longer than that in WT-CMs (Figures 3F,G). Y616C-CMs exhibited an abnormal AP profile, resembling that of a single triggered beat (Figure 3H).
FIGURE 3
We next introduced another known pathogenic mutation Y475C () into the KCNH2 gene to model LQT2 (Supplementary Figures 4A,B). We performed editing as described previously and note that the editing efficiency reached 53% on day 16 (Supplementary Figure 1D and Supplementary Table 2). We screened 41 single cell-derived clones, of which there were 18 heterozygous clones and 8 homozygous clones (Table 1). We recorded electrophysiology for the heterozygous Y475C-CMs by LEAP assay (Supplementary Figures 4C–G). Y475C-CMs showed longer APD and FPDc than WT-CMs. Y475C-CMs displayed triggered beats (Supplementary Figure 4H). Taken together, these data demonstrate that both Y616C-CMs and Y475C-CMs recapitulated LQT2 phenotype.
Base Editing of SCN5A for LQT3 Modeling
To model LQT3, we introduced a known pathogenic mutation E1784K () into the SCN5A gene of H9 cells (Figure 4A). The editing efficiency reached 21% on day 16 (Supplementary Figure 1E and Supplementary Table 2). We screened 107 single cell-derived clones, of which there were 32 heterozygous clones and 5 homozygous clones (Table 1). To test whether CMs exhibited the LQT3 phenotype, we differentiated heterozygous E1784K-H9 cells into CMs, and electrophysiology was recorded by the LEAP assay (Figure 4B). APD50 and APD90 in E1784K-CMs were significantly longer than those in WT-CMs (Figures 4C–E). FPDc in E1784K-CMs was significantly longer than that in WT-CMs (Figures 4F,G). These data demonstrated that base-edited E1784K-CMs successfully recapitulated LQT3 phenotype.
FIGURE 4
Evaluation of a Novel Mutation for Developing Brugada Syndrome
To demonstrate an additional application of epi-BEs, we use it to recapitulate and evaluate a novel mutation identified from a 62-year-old male patient who presented with sudden syncope. The patient’s resting electrocardiogram (ECG) showed an ST elevation in leads V1–V3 with a saddle-back appearance (Figure 5A), which is a characteristic pattern of BrS type 2 (). Genetic testing revealed a single missense mutation C5635T (R1879W) at the C-terminus of the SCN5A gene (Figure 5B).
FIGURE 5
To test whether R1879W is a pathogenic mutation, we used the epi-BEs to perform base editing and introduce it into H9 cells (Figure 5C). The editing efficiency reached 18% on day 16 (Supplementary Figure 1F and Supplementary Table 2). We screened 47 single cell-derived clones, of which there were 2 heterozygous clones and 8 homozygous clones (Table 1). To test whether CMs exhibited BrS phenotype, we differentiated heterozygous R1879W-H9 cells into CMs, and electrophysiology was recorded by the LEAP assay (Figure 5D). APD50, APD90, and FPDc of R1879W-CMs showed no significant difference compared with WT-CMs (Figures 5E–H), consistent with previous studies (; ). However, R1879W-CMs exhibited sustained triggered activity (Figure 5I), which is a typical characteristic of BrS patient-specific iPSC-derived CMs (). Taken together, these results demonstrated that these epi-BEs could evaluate and recapitulate the functions of a novel mutation identified from a patient.
Off-Target Analysis
The epi-BEs enable long-term editing due to continued expression, which may increase undesired off-target effects. We analyzed a panel of potential off-target sites for each single cell-derived clone that was used for electrophysiological recording (Supplementary Table 3). These potential off-target sites were selected using an online tool that identifies potential off-target sites (see footnote 2) (). These sites have at least three mismatches compared with the on-target sequences. The genomic DNA was extracted, and the potential off-target sites were PCR-amplified and subsequently sequenced by Sanger sequencing. Although cells were edited for 16 days, we did not detect any off-targets from these clones (Supplementary Figures 5–7). It is noteworthy to investigate the frequency of off-target cleavage by using whole genome sequencing in future studies.
Discussion
hPSCs have proven to be a powerful tool for developing therapeutics and modeling disease (; ). However, the generation of iPSCs from patients is a time-consuming and laborious process. Alternatively, mutations can be introduced into hPSCs by genome editing. developed a quick and efficient CRISPR/Cas9 genome editing procedure in iPSCs. We have previously demonstrated that the epiCRISPR system improves greatly the genome editing efficiency (Xie et al., 2017), but this technology can only introduce indels into cells for purposes of gene knockout. To overcome this limitation, we use the episomal vector to express base editors in this study, allowing the introduction of the pathogenic point mutations into hPSCs, which are more clinically relevant. This expanded technology further establishes the link between genome editing and hPSCs to enable future studies of diseases. Because the episomal vector can replicate in cells, there is an extended time possible for genome editing. As a result, higher editing efficiency has been achieved over time. Both heterozygous and homozygous mutations can be obtained and identified when analyzing single cells. The targeting range of ABEmax and AncBE4max is limited by the NGG PAM. To expand upon the targeting range of these tools, we can generate other versions of the episomal vector, which expresses other versions of base editors, such as SpCas9-NG- and SauriCas9-derived base editors (; ).
Our engineered hPSC-derived CMs successfully recapitulate disease phenotypes at the cellular level. We generate a total of five LQTS models, including two LQT1 models, two LQT2, models and one LQT3 model. All of these disease models display significantly prolonged APDs and FPDc, consistent with those of previous studies (; ; Yoshinaga et al., 2019). We finally evaluated a novel mutation identified from a BrS patient. Interestingly, this mutation does not influence APD and FPDc but induces sustained triggered beats, consistent with BrS phenotypes at cellular levels when studied previously (; ; ). In summary, these data demonstrate the utility of epi-BEs and provide the biomedical research community with a useful tool for diseasing modeling and deciphering novel mutations.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
Ethics statement
The studies involving human participants were reviewed and approved by Renji Hospital of Shanghai Jiao Tong University. The patients/participants provided their written informed consent to participate in this study.
Author contributions
All authors listed have made a substantial, direct and intellectual contribution to the work and approved it for publication.
Funding
This work was supported by grants from the National Natural Science Foundation of China (81870199 and 81970205), the Foundation for Innovative Research Group of the National Natural Science Foundation of China (31521003), the Beijing Natural Science Foundation (Z190013), the Opening Program 2018 of the State Key Laboratory of Genetic Engineering (SKLGE1809), and the Science and Technology Research Program of Shanghai (19DZ2282100).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2020.590581/full#supplementary-material
Footnotes
References
1
AndersonC. L.KuzmickiC. E.ChildsR. R.HintzC. J.DelisleB. P.JanuaryC. T. (2014). Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome.Nat. Commun.5:5535. 10.1038/ncomms6535
2
BaeS.ParkJ.KimJ. S. (2014). Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases.Bioinformatics301473–1475. 10.1093/bioinformatics/btu048
3
BarsheshetA.GoldenbergI.O-UchiJ.MossA. J.JonsC.ShimizuW.et al (2012). Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome.Circulation1251988–1996. 10.1161/circulationaha.111.048041
4
BrugadaJ.CampuzanoO.ArbeloE.Sarquella-BrugadaG.BrugadaR. (2018). Present status of brugada syndrome: JACC state-of-the-art review.J. Am. Coll. Cardiol.721046–1059. 10.1016/j.jacc.2018.06.037
5
BurridgeP. W.HolmstromA.WuJ. C. (2015). Chemically defined culture and cardiomyocyte differentiation of human pluripotent stem cells.Curr. Protoc. Hum. Genet.87:21.3.21-21.3.15. 10.1002/0471142905.hg2103s87
6
BurridgeP. W.MatsaE.ShuklaP.LinZ. C.ChurkoJ. M.EbertA. D.et al (2014). Chemically defined generation of human cardiomyocytes.Nat. Methods11855–860. 10.1038/nmeth.2999
7
ChadwickA. C.WangX.MusunuruK. (2017). In vivo base editing of PCSK9 (proprotein convertase subtilisin/kexin type 9) as a therapeutic alternative to genome editing.Arterioscler. Thromb. Vasc. Biol.371741–1747. 10.1161/ATVBAHA.117.309881
8
CongL.RanF. A.CoxD.LinS.BarrettoR.HabibN.et al (2013). Multiplex genome engineering using CRISPR/Cas systems.Science339819–823. 10.1126/science.1231143
9
El-BattrawyI.AlbersS.CyganekL.ZhaoZ.LanH.LiX.et al (2019). A cellular model of Brugada syndrome with SCN10A variants using human-induced pluripotent stem cell-derived cardiomyocytes.Europace211410–1421. 10.1093/europace/euz122
10
GaudelliN. M.KomorA. C.ReesH. A.PackerM. S.BadranA. H.BrysonD. I.et al (2017). Programmable base editing of A∗T to G∗C in genomic DNA without DNA cleavage.Nature551464–471. 10.1038/nature24644
11
GengB. C.ChoiK. H.WangS. Z.ChenP.PanX. D.DongN. G.et al (2020). A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.Acta Pharmacol. Sin.[Epub ahead of print]. 10.1038/s41401-020-0452-0
12
HayesH. B.NicoliniA. M.ArrowoodC. A.ChvatalS. A.WolfsonD. W.ChoH. C.et al (2019). Novel method for action potential measurements from intact cardiac monolayers with multiwell microelectrode array technology.Sci. Rep.9:11893. 10.1038/s41598-019-48174-5
13
HuZ.WangS.ZhangC.GaoN.LiM.WangD.et al (2020). A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope.PLoS Biol.18:e3000686. 10.1371/journal.pbio.3000686
14
ItzhakiI.MaizelsL.HuberI.Zwi-DantsisL.CaspiO.WintersternA.et al (2011). Modelling the long QT syndrome with induced pluripotent stem cells.Nature471225–229. 10.1038/nature09747
15
JinekM.ChylinskiK.FonfaraI.HauerM.DoudnaJ. A.CharpentierE. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.Science337816–821. 10.1126/science.1225829
16
JongbloedR.MarcelisC.VelterC.DoevendansP.GeraedtsJ.SmeetsH. (2002). DHPLC analysis of potassium ion channel genes in congenital long QT syndrome.Hum. Mutat.20382–391. 10.1002/humu.10131
17
KimH.KimJ. S. (2014). A guide to genome engineering with programmable nucleases.Nat. Rev. Genet.15321–334. 10.1038/nrg3686
18
KluesnerM. G.NedveckD. A.LahrW. S.GarbeJ. R.AbrahanteJ. E.WebberB. R.et al (2018). EditR: a method to quantify base editing from sanger sequencing.CRISPR J.1239–250. 10.1089/crispr.2018.0014
19
KoblanL. W.DomanJ. L.WilsonC.LevyJ. M.TayT.NewbyG. A.et al (2018). Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction.Nat. Biotechnol.36843–846. 10.1038/nbt.4172
20
KomorA. C.KimY. B.PackerM. S.ZurisJ. A.LiuD. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.Nature533420–424. 10.1038/nature17946
21
LanF.LeeA. S.LiangP.Sanchez-FreireV.NguyenP. K.WangL.et al (2013). Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells.Cell Stem Cell12101–113. 10.1016/j.stem.2012.10.010
22
LiX.LuW. J.LiY.WuF.BaiR.MaS.et al (2019). MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling.Cell Death Dis.10:610. 10.1038/s41419-019-1826-4
23
LiangP.LanF.LeeA. S.GongT.Sanchez-FreireV.WangY.et al (2013). Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.Circulation1271677–1691. 10.1161/circulationaha.113.001883
24
LiangP.SallamK.WuH.LiY.ItzhakiI.GargP.et al (2016). Patient-specific and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of brugada syndrome.J. Am. Coll. Cardiol.682086–2096. 10.1016/j.jacc.2016.07.779
25
LiuW. L.HuD. Y.LiP.LiC. L.QinX. G.LiY. T.et al (2006). [Novel mutations of potassium channel KCNQ1 S145L and KCNH2 Y475C genes in Chinese pedigrees of long QT syndrome].Zhonghua Nei Ke Za Zhi45463–466.
26
MaederM. L.GersbachC. A. (2016). Genome-editing technologies for gene and cell therapy.Mol. Ther.24430–446. 10.1038/mt.2016.10
27
MakitaN.BehrE.ShimizuW.HorieM.SunamiA.CrottiL.et al (2008). The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.J. Clin. Invest.1182219–2229. 10.1172/JCI34057
28
MaliP.YangL.EsveltK. M.AachJ.GuellM.DiCarloJ. E.et al (2013). RNA-guided human genome engineering via Cas9.Science339823–826. 10.1126/science.1232033
29
MillerD. C.HarmerS. C.PoliandriA.NoblesM.EdwardsE. C.WareJ. S.et al (2017). Ajmaline blocks INa and IKr without eliciting differences between Brugada syndrome patient and control human pluripotent stem cell-derived cardiac clusters.Stem Cell Res.25233–244. 10.1016/j.scr.2017.11.003
30
MossA. J. (2003). Long QT Syndrome.JAMA2892041–2044. 10.1001/jama.289.16.2041
31
NishimasuH.RanF. A.HsuP. D.KonermannS.ShehataS. I.DohmaeN.et al (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA.Cell156935–949. 10.1016/j.cell.2014.02.001
32
NishimasuH.ShiX.IshiguroS.GaoL.HiranoS.OkazakiS.et al (2018). Engineered CRISPR-Cas9 nuclease with expanded targeting space.Science3611259–1262. 10.1126/science.aas9129
33
ReesH. A.LiuD. R. (2018). Base editing: precision chemistry on the genome and transcriptome of living cells.Nat. Rev. Genet.19770–788. 10.1038/s41576-018-0059-1
34
TakahashiK.TanabeK.OhnukiM.NaritaM.IchisakaT.TomodaK.et al (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors.Cell131861–872. 10.1016/j.cell.2007.11.019
35
ThomsonJ. A.Itskovitz-EldorJ.ShapiroS. S.WaknitzM. A.SwiergielJ. J.MarshallV. S.et al (1998). Embryonic stem cell lines derived from human blastocysts.Science2821145–1147. 10.1126/science.282.5391.1145
36
Van CraenenbroeckK.VanhoenackerP.HaegemanG. (2000). Episomal vectors for gene expression in mammalian cells.Eur. J. Biochem.2675665–5678. 10.1046/j.1432-1327.2000.01645.x
37
WangB.WangZ.WangD.ZhangB.OngS. G.LiM.et al (2019). krCRISPR: an easy and efficient strategy for generating conditional knockout of essential genes in cells.J. Biol. Eng.13:35. 10.1186/s13036-019-0150-y
38
WangY.LiangP.LanF.WuH.LisowskiL.GuM.et al (2014). Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing.J. Am. Coll. Cardiol.64451–459. 10.1016/j.jacc.2014.04.057
39
WangY.ZhangW. Y.HuS.LanF.LeeA. S.HuberB.et al (2012). Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging.Circ. Res.1111494–1503. 10.1161/circresaha.112.274969
40
WildeA. A. M.AminA. S. (2018). Clinical spectrum of SCN5A mutations: long qt syndrome, brugada syndrome, and cardiomyopathy.JACC Clin. Electrophysiol.4569–579. 10.1016/j.jacep.2018.03.006
41
XieY.MaA.WangB.PengR.JingY.WangD.et al (2019). Rare mutations of ADAM17 from TOFs induce hypertrophy in human embryonic stem cell-derived cardiomyocytes via HB-EGF signaling.Clin. Sci.133225–238. 10.1042/cs20180842
42
XieY.WangD.LanF.WeiG.NiT.ChaiR.et al (2017). An episomal vector-based CRISPR/Cas9 system for highly efficient gene knockout in human pluripotent stem cells.Sci. Rep.7:2320. 10.1038/s41598-017-02456-y
43
YoshinagaD.BabaS.MakiyamaT.ShibataH.HirataT.AkagiK.et al (2019). Phenotype-based high-throughput classification of long QT syndrome subtypes using human induced pluripotent stem cells.Stem Cell Rep.13394–404. 10.1016/j.stemcr.2019.06.007
Summary
Keywords
human pluripotent stem cell, base editing, episomal vector, disease modeling, IPS, long QT syndrome, Brugada syndrome
Citation
Qi T, Wu F, Xie Y, Gao S, Li M, Pu J, Li D, Lan F and Wang Y (2020) Base Editing Mediated Generation of Point Mutations Into Human Pluripotent Stem Cells for Modeling Disease. Front. Cell Dev. Biol. 8:590581. doi: 10.3389/fcell.2020.590581
Received
02 August 2020
Accepted
08 September 2020
Published
25 September 2020
Volume
8 - 2020
Edited by
Mingtao Zhao, Nationwide Children’s Hospital, United States
Reviewed by
Hua Zhu, The Ohio State University, United States; Won Hee Lee, University of Arizona, United States
Updates
Copyright
© 2020 Qi, Wu, Xie, Gao, Li, Pu, Li, Lan and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yongming Wang, ymw@fudan.edu.cnFeng Lan, fenglan@ccmu.edu.cn
†These authors have contributed equally to this work
This article was submitted to Stem Cell Research, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.